Delivery Order SPE2DB22D2211-SPE2DB25FRSMP

Award Date 3/3/25
Potential Completion Date 3/4/25
Potential Value $17K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product, with a ceiling value of $15,622.39 and a completion date of March 5, 2024. The contract is a firm fixed-price, open competition award with no set-aside designation. Amerisourcebergen holds a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product, with a ceiling value of $15,836.43 and a performance period through May 28, 2024. This order is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This federal contract award is for the delivery of PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract, valued at $16,073.22, was awarded to prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. This is a delivery order contract with a firm fixed price pricing type, and the ultimate completion date is August 1, 2023. The contract is not designated with any set-aside...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,849.28, is for the delivery of PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product. The contract has a firm fixed price and is a delivery order, with a period of performance through November 29, 2024. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that...
This federal contract award is an order placed under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen Drug Corp, a major pharmaceutical distributor, with the Defense Logistics Agency (DLA) Troop Support Medical. The award covers the delivery of PULMOZYME 1 MG/ML AMPUL 2.5ML, a specialty medication, with a ceiling value of $7,275.43 and a completion date of January 28, 2025. The contract is a Firm Fixed Price Delivery Order, with no set-aside designation. AmerisourceBergen, a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,365.64 firm fixed-price delivery order covers the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product, with a completion date of February 5, 2025. The award is associated with a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a specialty pharmaceutical product. The contract has a ceiling value of $2,701.27 and a performance period ending on September 30, 2024. It is a firm-fixed price contract, and there is no set-aside designation. Amerisourcebergen, a major pharmaceutical distributor, is the prime contractor for this award, which is likely part of a larger Indefinite...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,563,455,548 units of the pharmaceutical product PULMOZYME 1 MG/ML AMPUL 2.5ML. The contract has a completion date of January 29, 2024 and a potential value of $6,236.58. This delivery order is issued under a larger indefinite delivery contract (IDC) awarded to Amerisourcebergen Drug Corp by DLA with a potential...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,122.56, is for the provision of PULMOZYME 1 MG/ML AMPUL 2.5ML, a specialty pharmaceutical product. The contract has an ultimate completion date of November 14, 2024 and is a firm fixed-price delivery order. The contract is not designated as a set-aside. AmerisourceBergen Drug Corp...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,125.94 firm fixed-price contract is for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a specialty medication. The contract has an ultimate completion date of December 30, 2024 and was awarded on December 27, 2024. This award is associated with AmerisourceBergen's Indefinite...
  • SPE2DB22D2211
    Indefinite Delivery Contract
  • SPE2DB22D2211-SPE2DB25FRSMP
    Delivery Order

This contract award is for the delivery of PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract has a ceiling value of $17,152.30 and is a firm fixed-price delivery order that runs through March 4, 2025. The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. This contract is part of a larger Indefinite Delivery Contract (IDC) the company holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 6/2/25, 9:47 AM